Board welcomes two trustees, recognizes three life trustees
At a May meeting, the University Board of Trustees elected two new members, and recognized three members on becoming life trustees.
Novel imaging system could mean near-instant biopsy results
The new imaging system developed by Michael Giacomelli, an assistant professor of biomedical engineering and of optics, uses two-photon fluorescence microscopy (TPFM).
Bedside art appreciation eases cancer patients’ anxiety
Looking at and discussing curated art, including works from the University’s Memorial Art Gallery collection, helped calm a group of cancer patients.
Rochester researchers seek ‘direct hit’ on leukemic stem cells
An internal funding program, plus the close proximity of the University’s engineering and medical facilities, promotes progress in a potential treatment for acute myeloid leukemia.
Meet one of Popular Science magazine’s ‘Brilliant 10’
Rochester biomedical engineer Michael Giacomelli is pursuing a quicker way to detect skin cancer.
Listening to family stories helps cancer researchers identify gaps in care
A Wilmot Cancer Institute study of more than 90 families and caregivers looked for common threads about their loved one’s final transition from active treatment to death and dying.
Three appointed to named professorships
Thu Le, professor of medicine; Paula Vertino, professor of biomedical genetics; and David Herrmann, professor of neurology; have each been recently appointed to named professorships.
How can a single gene be at fault in one of the deadliest cancers?
A breakthrough study from Rochester’s Wilmot Cancer Institute gives researchers hope that new gene-targeted therapies could improve survival rates for acute myeloid leukemia, which have not budged in years.
Research is changing the game for melanoma treatment
Some Wilmot Cancer Institute patients with advanced melanoma may have longer disease-free survival thanks to new drug treatment options tested by Rochester researchers.
Pancreatic tumors may require a one-two-three punch
Wilmot Cancer Institute scientists have discovered that a three-drug combination can simultaneously target the cancer cells as well as the other harmful, inflammatory cells within the tumor.